Christopher Power, University of Alberta (IMAGE)

University of Alberta Faculty of Medicine & Dentistry

Christopher Power, University of Alberta

Caption

U of A researcher Christopher Power and his team found that administering an anti-inflammatory drug called VX-765 through the nose slowed the progression of multiple sclerosis in a preclinical model.

Credit

University of Alberta

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.